Differences between BNT162b2 and Comirnaty®
ASE made this Official Information request to Ministry of Health
This request has an unknown status. We're waiting for ASE to read a recent response and update the status.
From: ASE
Attn Ministry of Health,
I am seeking information regarding substantive differences between BNT162b2 and Comirnaty®.
Both products have variously been referred to as “COVID-19 vaccines” and “vaccine candidates”.
1- Are/were the same manufacturing processes used to manufacture Comirnaty® and BNT162b2? Has The Ministry of Health confirmed such information with the manufacturer/supplier?
2- What information is held by The Ministry of Health regarding similarities and differences between the manufacturing processes of BNT162b2 and Comirnaty®?
3- Are there any quantifiable differences between BNT162b2 and Comirnaty®, eg regarding the use or presence of SV40 sequences, the presence of DNA, the integrity of synthetic mRNA, the use of methyl-pseudouridine, or any other quantifiable differences?
Thank you,
ASE
From: OIA Requests
Kia ora
Thank you for your request for official information. The reference number
for your request is: H2024041059
As required under the Official Information Act 1982, Manatū Hauora will
endeavour to respond to your request no later than 20 working days after
the day your request was received. If you'd like to calculate the
timeframe, you can use the Ombudsman's online calculator
here: [1]http://www.ombudsman.parliament.nz/
If you have any queries, please feel free to contact the OIA Services Team
on [2][email address]. If any additional factors come to light which
are relevant to your request, please do not hesitate to contact us so that
these can be taken into account.
Under section 28(3) of the Act you have the right to ask the Ombudsman to
review any decisions made under this request. The Ombudsman may be
contacted by email at: [3][email address] or by calling 0800
802 602.
Ngā mihi
OIA Services Team
[4]Ministry of Health information releases
------------------- Original Message
show quoted sections
From: OIA Requests
Kia ora ASE,
Please find attached our response to your official information request.
Ngā mihi
OIA Services Team
Manatū Hauora | Ministry of Health
M[1]inistry of Health information releases
U[2]nite against COVID-19
show quoted sections
References
Visible links
1. https://www.health.govt.nz/about-ministr...
2. https://covid19.govt.nz/
From: ASE
Attn, Ministry of Health
As this Ministry is responsible for assuring the safety and efficacy of approved medical interventions in NZ,
And as pharmaceutical and especially biological safety regulations widely recognises that “the process is the product”,
I expect that the Ministry can provide a substantive answer, rather than deferring to common industry practice. If the Ministry of Health can not directly answer this question, then please clearly state that.
Did the manufacturing processes used to obtain any kind of regulatory approval for any “COVID-19 vaccines” and covid “vaccine candidates” significantly and materially change since the applications for approval were first submitted?
As more reports have been indicating that manufacturing methods did significantly change subsequent to applications for approval being made, what actions has the Ministry of Health taken to investigate such claims? eg, has the Ministry of Health directly questioned the suppliers, applicants, and other stakeholders about this?
Thank you,
ASE
From: OIA Requests
Kia ora ASE,
Thank you for your request for official information. The Ministry's
reference number for your request is: H2025059109.
Please be advised that due dates for requests received from 27 November
2024 onwards will take into account the summer holidays (25 December 2024
to 15 January 2025). Please refer to this guide for an explanation of
the [1]statutory obligations under the Official Information Act 1982.
You can expect a reply no later than 24 February. If we are unable to
respond to your request within this time frame, we will notify you of an
extension of that time frame.
If you have any queries related to this request, please do not hesitate to
get in touch.
Ngā mihi
OIA Services Team
[2]Ministry of Health information releases
Attn, Ministry of Health
As this Ministry is responsible for assuring the safety and efficacy of
approved medical interventions in NZ,
And as pharmaceutical and especially biological safety regulations widely
recognises that “the process is the product”,
I expect that the Ministry can provide a substantive answer, rather than
deferring to common industry practice. If the Ministry of Health can not
directly answer this question, then please clearly state that.
Did the manufacturing processes used to obtain any kind of regulatory
approval for any “COVID-19 vaccines” and covid “vaccine candidates”
significantly and materially change since the applications for approval
were first submitted?
As more reports have been indicating that manufacturing methods did
significantly change subsequent to applications for approval being made,
what actions has the Ministry of Health taken to investigate such claims?
eg, has the Ministry of Health directly questioned the suppliers,
applicants, and other stakeholders about this?
Thank you,
ASE
show quoted sections
References
Visible links
1. https://www.ombudsman.parliament.nz/reso...
https://www.ombudsman.parliament.nz/reso...
2. https://www.health.govt.nz/about-ministr...
Things to do with this request
- Add an annotation (to help the requester or others)
- Download a zip file of all correspondence
Offensive? Unsuitable?
Requests for personal information and vexatious requests are not considered valid requests for Official Information (read more).
If you believe this request is not suitable, you can report it for attention by the site administrators
Report this requestAct on what you've learnt
Similar requests
Consolidated request re COVID-19 inoculations, safety, efficacy, necessity, policy roles, etc
To Ministry of Health by ASE
